Drug intelligence / Profile preview

henplatin

Development stage: Unknown
Lead developer: Goodfellow Pharma
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

Henplatin is a platinum-based small molecule antineoplastic agent developed by Goodfellow Pharma. It functions by targeting DNA, where it forms covalent adducts and cross-links that disrupt DNA replication and transcription processes. This mechanism of action leads to DNA damage-induced apoptosis, particularly in rapidly proliferating tumor cells. Henplatin is approved for the treatment of colorectal cancer, providing a therapeutic option designed to interfere with tumor cell replication and disease progression.

Brand names: HENPLATIN

Targets

DNA

Beyond the preview

Go deeper on henplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on henplatin.

Explore the full profile